Neuropeptide-Y
Cross-source consensus on Neuropeptide-Y from 1 sources and 3 claims.
1 sources · 3 claims
Uses
How it works
Highlighted claims
- Neuropeptide-Y has strong proarrhythmic effects that persist even during maximal beta-blockade. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
- The proarrhythmic effects of neuropeptide-Y are mediated through ventricular myocyte Y1 receptor promotion of calcium signalling. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
- Neuropeptide-Y may act as a biomarker of arrhythmic risk and predicts arrhythmia and death in chronic heart failure and after myocardial infarction. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia